date:Feb 11, 2014
of scale offered by a fully-automated system.
Business development manager Aaron Tohill explained the rationale behind the move, As the reputation of our patented multiplex drug residue screening system, BioChip Array Technology, continues to grow within the honey market, we've found the interest at Conferences and Exhibitions a revelation.
Therefore we decided, rather than wait for events coming around, we would proactively create opportunities for the industry to experience BioChip Array for